Superficial mycoses in immunodepressed patients (AIDS)

Area of Science:

• Medical Mycology
• Infectious Diseases
• Immunocompromised Host

Background:

• Human immunodeficiency virus (HIV) infection significantly impacts the epidemiology and clinical presentation of various infectious diseases.
• Superficial fungal infections are notably prevalent in individuals with HIV/AIDS, often exhibiting atypical manifestations and altered disease courses.
• Immunocompromised status in HIV patients can lead to modified or exacerbated superficial mycoses.

Purpose of the Study:

• To provide a comprehensive overview of the diagnosis and treatment strategies for superficial fungal infections in the context of HIV.
• To highlight the unique challenges and considerations for managing mycoses in HIV-positive individuals.
• To discuss specific cutaneous fungal pathogens encountered in HIV patients.

Main Methods:

• Review of current literature on superficial mycoses in HIV-infected individuals.
• Discussion of diagnostic approaches for common fungal pathogens.
• Outline of therapeutic options for superficial fungal infections in immunocompromised patients.

Main Results:

• Superficial fungal infections present differently in HIV patients, requiring tailored diagnostic and treatment protocols.
• Commonly implicated fungi include Candida species, dematiaceous fungi (causing phaeohyphomycosis), Malassezia species, dermatophytes, and non-dermatophyte filamentous fungi.
• Atypical presentations and disease exacerbations are characteristic of these infections in the context of altered immunity.

Conclusions:

• Effective management of superficial mycoses in HIV patients necessitates understanding their altered immune status and potential for atypical disease presentations.
• Prompt and accurate diagnosis is crucial for initiating appropriate antifungal therapy.
• Treatment strategies must be individualized based on the specific fungal agent, clinical manifestation, and degree of immunosuppression.